SDZ 210086Alternative Names: SDZ BOP 086
Latest Information Update: 22 Jan 1997
At a glance
- Originator Novartis
- Class Analgesics; Antipyretics; Muscle relaxants; Nootropics
- Mechanism of Action Muscarinic M1 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 22 Jan 1997 No-Development-Reported for Alzheimer's disease in Switzerland (Unknown route)